|
49 |
Complement pathway inhibition by LHR domain-based duplication variants of Complement Receptor 1. Sandra Wymann1, Anup Gopinathan Nair2, Svenja Ewert1, Glenn Powers2, Adriana Baz Morelli2, Tony Rowe2, and Matthew P. Hardy2
|
|
50 |
CORVOS (2019-2024) – facilitating more PhD student exchanges and working towards a European Complement PhDReinhard Würzner
|
|
51 |
Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected epithelial cellsHang Zhong1, Matteo Stravalaci4, Isabel Pagani3, Niloufar Kavian-Tessler 1, Poli Guido3, Seppo Meri4, Barbara Bottazzi1, Elisa Vicenzi3, and Cecilia Garlanda1
|
|
52 |
Structure-function analysis of ARGX-117, a calcium- and pH-dependent clinical phase complement C2 blocking antibody Laura Bracke1, Heidi Gytz Olesen2, Erwin Pannecoucke1, Tim Delahaye1, Emma K Persson1, Erik C Hack1, Gregers Rom Andersen2, and Inge Van de Walle1
|
|
53 |
Dynamic changes in Cytokines and Complement biomarkers during COVID-19: Implications for disease severity and outcomes.Andrea N Moreno-Amaral, Marina Castro de Deus, Ana Carolina Gadotti, Gabriela Bohnen Andrade, Erika Sousa Dias, Julia Bacarin Monte Alegre, Beatriz Akemi Von Spitzenbergen, and Sara Soares Tozoni
|
|
54 |
Titration of the biological activities Anaphylatoxins using reporter cell lines Rosa Ferrando-Miguel and Emilie Gobbo
|
|
55 |
selection and characterization of a peptide-based complement activator Sebastiaan M.W.R. Hamers1, Thomas H. Sharp2, and Aimee L. Boyle3
|
|
56 |
Investigating the impact of complement sources and Complement Factor H (CFH) Y402H polymorphism on the stress response of iPSC-RPE cellsAngela Armento1, Inga Sonntag1, Simon J Clark1, Rosario Fernandez-Godino2, Berta de la Cerda3, and Marius Ueffing1
|
|
57 |
Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibioticsOle L. Brekke1,2, Ingrid S. Joakimsen1, Baard O. Karlsen1,3, Åse E. Emblem3, Kristin Pettersen3, Renathe H. Grønli3, Corinna Lau3, John D. Lambris4, and Tom E. Mollnes3,5
|
|
58 |
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics Klaudia Kulak, Selvi Celik, Viktoria Kozma, Cecilia Klint, Benoit Vallette, Camilla Nilsson, Christophe Lallemand, Lone Bovin, Jordi Rodó, Samuel Butler, and Michael Schwenkert
|
|
59 |
Selective suppression of pathogenic B lymphocytes from Hashimoto's thyroiditis patients by chimeric protein molecules Andrey Tchorbanov1, Nikola Ralchev1, Irini Doychinova2, Iliyan Manoylov1, Nikolina Mihaylova1, and Alexander Shinkov3
|
|
60 |
Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity moleculesVirginia Cianchi1,2, Matteo Stravalaci1,3, Isabel Pagani4, Alessandro Ajò7, Luisa De Cola5,6,7, Elisa Vicenzi4, Alberto Mantovani1,2,8, and Cecilia Garlanda1,2
|
|
61 |
A method to determine the inhibitor potential of the blood to predict uncontrolled activation of the complement systemBatozhab Batozhargalovich Shoibonov
|
|
62 |
Further insights into iptacopan mode of action in IgA nephropathy through protein profilingAndrea Grioni1,2, Mykola Lysetskiy1,2, Anna Schubart1,2, Marie-Anne Valentin1,2, Dmitrij Kollins3, Imelda Schuhmann1,2, Anastasiia Zub4, Oksana Ikkert4, Oleksandr Karmash4, and Yaryna Shalai4
|
|
63 |
History of a success: setting proximal complement inhibitors as new treatment paradigm for Paroxysmal Nocturnal HemoglobinuriaAntonio M Risitano
|
|
64 |
Granzyme K activates a new complement pathwayCarlos A Donado1, Erin Theisen1, Anna H Jonsson2, and Michael B Brenner1
|
|
65 |
Targeting the Hypothalamic Complement System: A Novel Approach to Combatting ObesityCarolin Gragoll, Timo Rusack, Michael Schneider, Ingo Eitel, Zouhair Aherrahrou, and Elias Rawish
|
|
66 |
Obesity and metabolic health shapes mucosal complement responsesDevesha H Kulkarni, Khushi Talati, Ayse Ozanturk, Dalia Harris, Rafael Alburquerque Aponte, Hrishi Kousik, and Hrishikesh S Kulkarni
|
|
67 |
Understanding the effects of ARMS2 and its AMD risk variant A69S on extracellular matrix and complement systemMerve Sen, Angela Armento, and Marius Ueffing
|
|
68 |
BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseases.Mikael Winkler, Dennis Pedersen , Heidi Gytz, Mikael Winkler , Pascal Merchiers, Krishna Polu, and Nick Laursen
|
|
69 |
Complement Activity in Emboli Retrieved During Thrombectomy for Ischemic Stroke E. Sander Connolly Jr.
|
